Tuesday, February 02, 2021 1:25:18 PM
Cassava Sciences (SAVA) presented the phase 2b data on its lead drug, Sumifilam, from its re-analysis. The results look impressive from the view of biomarkers, although the new analysis is not blinded. Initial analysis by an independent company in a blinded fashion showed no effect from treatment.
The impact on memory through 28 days showed some improvement but not statistically significant (tip for Hedges’ g value: 20%, no one sees the difference; 50%, some can see a difference; 80%, most can see a difference). There are not enough details in the press release for more solid assessment. It would be nice to know all the responses from each patient. Nevertheless, the results will propel SAVA to initiate phase 3 registration trial once funding is secured. The likely scenario is through a partnership by giving up 30% of company for $300 million. The price target is $35 upon securing a partnership.
In the same space, Anavex (AVXL) targets sigma-1 receptor with two candidates, 2-73 and 3-71. There is some impressive data for a sub-group of patients who has been on 2-73 for over four years without symptom deterioration. More importantly, 2-73 has been in a registration trial for AD for over two years and most likely is ahead of SAVA three years.
Now the question is: which company has the more promising drug?
Sumifilam (PTI-125) is developed by Cassava Sciences to target filamin A, which is a central structural protein for inflammatory responses. Anavex has developed 2-73 and 3-71 to target sigma-1 receptor, a critical protein for various stress responses as well as BBB maintenance. Sumifilam, Anavex 2-73, or Anavex 3-71 are all from thinly published scientific literature and outside the mainstream amyloid-cascade hypothesis. That is the likely reason for their meager market-cap. However, these findings do shed new light on AD studies as amyloid theory has been questioned more recently.
Then what are the valid molecular targets for these compounds? We have conducted extensive analysis by structural comparison and docking to sigma-1 receptor and filamin A. The conclusion is that all three compounds most likely have the same sets of molecular targets (chemical structure in Figure 1, and visualization for similarities from Figure 2).
Figure 1: Structural Comparison of Leading Compounds.
Figure 1: Structural Comparison of Leading Compounds.
(see link)
1. All three compounds are agonists of sigma-1 receptor, with affinities in descending order: 3-71 > Sumifilam > 2-73. The tertiary amine with a methyl group is essential for the binding as it mimics the head-group of choline. After all, sigma-1 receptor is a low-affinity choline receptor first. Stimulating sigma-1 receptor is critical for the restoration of blood-brain-barrier (BBB). A leaky/damaged BBB is a common feature among AD patients. The primary metabolite of 2-73 has similar affinity towards sigma-receptor to that of Sumifilam.
2. All three compounds have high affinities towards filamin A. Docking studies indicate that the affinities are in comparable range for all three with 3-71 slightly weaker. Binding to filamin A is critical for reducing inflammation.
3. Additional molecular targets have also been identified (not disclosed here). All three compounds bind to those targets.
Figure 2. The Shared structure of the three compounds. The tertiary amine (6-member ring) and 5-member ring structures bind to sigma-1 receptor.
Figure 2. The Shared structure of the three compounds. The tertiary amine (6-member ring) and 5-member ring structures bind to sigma-1 receptor.
(see link)
Despite the different approaches from SAVA and AVXL, it is interesting to note that both arrive at similar molecules for treating AD. This bodes well for both companies with AVXL in the lead for about 3 years. We project AVXL to be in the $40~45 range per share within a year with positive Rett result, partially positive result from Parkinson trial (positive only for those patients with certain genetic markers) and the completion of recruitment for AD trial.
(Also see falconer's post coving the analysis of AVXL vs SAVA, with 2-73 Blarcamesine treating upstream ahead of the SAVA drug)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161424935
Results from Cassava Sciences: https://www.cassavasciences.com/static-files/f7e26ba8-7e56-4ff5-8bc1-fe1614fa4eba
Anavex corporate presentation: https://www.anavex.com/wp-content/uploads/2020/02/Anavex-Presentation-February-2020.pdf
Clinical trials of 2-73 and 3-71 from Anavex: https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=anavex&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
Many Thanks Ripper for posting the link:
https://www.biotechtoinvest.com/research/2020/9/15/all-roads-lead-to-rome-compounds-from-avxl-and-sava-likely-target-the-same-sets-of-molecules?fbclid=IwAR3SBYqA75v8WxbnDXFW356fj3ymBzFx4b8I4nayiHSE9pGPtxvx4KX8eW0
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM